SOUTH SAN FRANCISCO, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today announced that it is offering to sell, subject to market and other conditions, 6,000,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. It is currently anticipated that the underwriters will be granted an over-allotment option for an additional 900,000 shares.
A preliminary prospectus supplement relating to these securities will be filed with the Securities and Exchange Commission but remains subject to completion. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.
About Rigel
Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases.
Photo: http://www.newscom.com/cgi-bin/prnh/20030226/RIGLLOGO
http://photoarchive.ap.org
PRN Photo Desk photodesk@prnewswire.comRigel Pharmaceuticals, Inc.
